Active Not Recruiting PHASE3 INTERVENTIONAL 3-arm NCT01953588

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study

Sponsor: Alliance for Clinical Trials in Oncology

Conditions Estrogen Receptor-positive Breast Cancer HER2-negative Breast Cancer Invasive Ductal Breast Carcinoma Invasive Lobular Breast Carcinoma Recurrent Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer

Interventions anastrozole fulvestrant

Updated 30 times since 2017 Last updated: Jan 20, 2026 Started: Feb 27, 2014 Primary completion: Apr 1, 2027 Completion: Apr 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Estrogen Receptor-positive Breast Cancer and HER2-negative Breast Cancer and is currently ongoing. Alliance for Clinical Trials in Oncology leads this study, which shows 30 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

30 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Feb 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Feb 2025 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3

▶ Show 25 earlier versions

Sep 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE3
Sep 2022 — Sep 2023 [monthly]

Active Not Recruiting PHASE3
Sep 2021 — Sep 2022 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE3
Jul 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Nov 2019 — Jul 2020 [monthly]

Active Not Recruiting PHASE3
Sep 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jul 2019 — Sep 2019 [monthly]

Recruiting PHASE3
Mar 2019 — Jul 2019 [monthly]

Recruiting PHASE3
Feb 2019 — Mar 2019 [monthly]

Recruiting PHASE3
Jan 2019 — Feb 2019 [monthly]

Recruiting PHASE3
Oct 2018 — Jan 2019 [monthly]

Recruiting PHASE3
Aug 2018 — Oct 2018 [monthly]

Recruiting PHASE3
Jul 2018 — Aug 2018 [monthly]

Recruiting PHASE3
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE3
May 2018 — Jun 2018 [monthly]

Recruiting PHASE3
Mar 2018 — May 2018 [monthly]

Recruiting PHASE3
Feb 2018 — Mar 2018 [monthly]

Recruiting PHASE3
Oct 2017 — Feb 2018 [monthly]

Recruiting PHASE3
Jul 2017 — Oct 2017 [monthly]

Recruiting PHASE3
Jun 2017 — Jul 2017 [monthly]

Recruiting PHASE3
May 2017 — Jun 2017 [monthly]

Recruiting PHASE3
Mar 2017 — May 2017 [monthly]

Recruiting PHASE3
Feb 2017 — Mar 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Abilene, United States , Albuquerque, United States , Allentown, United States , Anaconda, United States , Anacortes, United States , Anchorage, United States , Anderson, United States , Ann Arbor, United States , Antigo, United States and 487 more locations